Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher T Ritchlin

Showing results (171-180 of 200) with videos related to

Pageof 20
Sort By:
Annals of the Rheumatic Diseases|September 11, 2023
Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL studyChristopher T Ritchlin, Laura C Coates, Iain B McInnes, et al.
Pharmacology & Therapeutics|June 25, 2021
Secukinumab for the treatment of psoriasis, psoriatic arthritis, and axial spondyloarthritis: Physical and pharmacological properties underlie the observed clinical efficacy and safetyFrank Kolbinger, Franco Di Padova, Atul Deodhar, et al.
Molecular Medicine (Cambridge, Mass.)|April 20, 2006
Microarray analyses of peripheral blood cells identifies unique gene expression signature in psoriatic arthritisFranak M Batliwalla, Wentian Li, Christopher T Ritchlin, et al.
Lancet (London, England)|December 9, 2022
Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL)Iain B McInnes, Akihiko Asahina, Laura C Coates, et al.
Rheumatology (Oxford, England)|April 6, 2021
Resolution of enthesitis by guselkumab and relationships to disease burden: 1-year results of two phase 3 psoriatic arthritis studiesDennis McGonagle, Iain B McInnes, Atul Deodhar, et al.
The Journal of Rheumatology|February 12, 2010
Imaging in psoriasis and psoriatic arthritis: GRAPPA 2008Laura C Coates, Dennis M McGonagle, Richard Hodgson, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 11, 2020
Tumor Necrosis Factor Induces Obliterative Pulmonary Vascular Disease in a Novel Model of Connective Tissue Disease-Associated Pulmonary Arterial HypertensionRichard D Bell, R James White, Maria L Garcia-Hernandez, et al.
RMD Open|March 17, 2022
Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studiesChristopher T Ritchlin, Philip J Mease, Wolf-Henning Boehncke, et al.
The Journal of Rheumatology|May 2, 2021
Pooled Safety Results Through 1 Year of 2 Phase III Trials of Guselkumab in Patients With Psoriatic ArthritisProton Rahman, Christopher T Ritchlin, Philip S Helliwell, et al.
Arthritis Research & Therapy|December 20, 2011
Decreased influenza-specific B cell responses in rheumatoid arthritis patients treated with anti-tumor necrosis factorJames J Kobie, Bo Zheng, Peter Bryk, et al.
Pageof 20

Showing results (171-180 of 200) with videos related to

Sort By:
Pageof 20
Annals of the Rheumatic Diseases|September 11, 2023
Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL studyChristopher T Ritchlin, Laura C Coates, Iain B McInnes, et al.
Pharmacology & Therapeutics|June 25, 2021
Secukinumab for the treatment of psoriasis, psoriatic arthritis, and axial spondyloarthritis: Physical and pharmacological properties underlie the observed clinical efficacy and safetyFrank Kolbinger, Franco Di Padova, Atul Deodhar, et al.
Molecular Medicine (Cambridge, Mass.)|April 20, 2006
Microarray analyses of peripheral blood cells identifies unique gene expression signature in psoriatic arthritisFranak M Batliwalla, Wentian Li, Christopher T Ritchlin, et al.
Lancet (London, England)|December 9, 2022
Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL)Iain B McInnes, Akihiko Asahina, Laura C Coates, et al.
Rheumatology (Oxford, England)|April 6, 2021
Resolution of enthesitis by guselkumab and relationships to disease burden: 1-year results of two phase 3 psoriatic arthritis studiesDennis McGonagle, Iain B McInnes, Atul Deodhar, et al.
The Journal of Rheumatology|February 12, 2010
Imaging in psoriasis and psoriatic arthritis: GRAPPA 2008Laura C Coates, Dennis M McGonagle, Richard Hodgson, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 11, 2020
Tumor Necrosis Factor Induces Obliterative Pulmonary Vascular Disease in a Novel Model of Connective Tissue Disease-Associated Pulmonary Arterial HypertensionRichard D Bell, R James White, Maria L Garcia-Hernandez, et al.
RMD Open|March 17, 2022
Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studiesChristopher T Ritchlin, Philip J Mease, Wolf-Henning Boehncke, et al.
The Journal of Rheumatology|May 2, 2021
Pooled Safety Results Through 1 Year of 2 Phase III Trials of Guselkumab in Patients With Psoriatic ArthritisProton Rahman, Christopher T Ritchlin, Philip S Helliwell, et al.
Arthritis Research & Therapy|December 20, 2011
Decreased influenza-specific B cell responses in rheumatoid arthritis patients treated with anti-tumor necrosis factorJames J Kobie, Bo Zheng, Peter Bryk, et al.
Pageof 20